extract: 2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/health/CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo.md

@@ -30,6 +30,12 @@ The investment implication: companies positioned at the category I boundary —
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm]] | Added: 2026-03-31*
+
+TEMPO + CMS ACCESS model formalizes a two-speed system at an earlier stage: pre-clearance devices get Medicare reimbursement through ACCESS while collecting evidence, versus cleared devices with standard coverage. This creates a research-to-reimbursement pathway that didn't exist before January 2026, but scale is limited to ~10 manufacturers per clinical area.
+
+
 Relevant Notes:
 - [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — the static-code problem applies to CMS as well as FDA
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — AI codes could bridge the payment gap

domains/health/rpm-technology-stack-enables-facility-to-home-care-migration-through-ai-middleware-that-converts-continuous-data-into-clinical-utility.md

@@ -35,6 +35,12 @@ McKinsey identifies RPM as the fastest-growing home healthcare end-use segment a
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm]] | Added: 2026-03-31*
+
+TEMPO enables RPM deployment at the infrastructure level by providing both FDA enforcement discretion and CMS reimbursement for digital health devices targeting hypertension. However, this infrastructure is Medicare-only and research-scale (10 manufacturers), not a population-level deployment mechanism.
+
+
 Relevant Notes:
 - [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]]
 - [[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]

domains/health/tempo-pilot-creates-medicare-digital-health-pathway-while-medicaid-coverage-contracts.md

@@ -0,0 +1,36 @@
+---
+type: claim
+domain: health
+description: FDA's TEMPO + CMS ACCESS model enables digital health for Medicare patients targeting hypertension while OBBBA Medicaid cuts remove coverage for the demographic with highest non-control rates
+confidence: experimental
+source: FDA TEMPO pilot announcement (Dec 2025), CMS ACCESS model documentation
+created: 2026-03-31
+attribution:
+  extractor:
+    - handle: "vida"
+  sourcer:
+    - handle: "u.s.-food-and-drug-administration"
+      context: "FDA TEMPO pilot announcement (Dec 2025), CMS ACCESS model documentation"
+related: ["the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification"]
+---
+
+# The TEMPO pilot creates Medicare digital health infrastructure while simultaneous Medicaid coverage contraction creates a structural divergence where regulatory innovation serves the elderly while coverage loss affects working-age populations with worse hypertension outcomes
+
+The TEMPO pilot represents the first combined FDA enforcement-discretion + CMS reimbursement pathway for digital health devices, explicitly targeting hypertension in the 'early cardio-kidney-metabolic' category. Up to 10 manufacturers per clinical area can deploy uncleared devices to Medicare patients in the ACCESS model while collecting real-world evidence. This creates genuine market entry infrastructure that didn't exist before January 2026.
+
+However, TEMPO operates exclusively within Medicare (65+ population) through the ACCESS model. The source notes explicitly state that 'The population with the worst hypertension control rates (low-income, food-insecure, working-age) is primarily in Medicaid, not Medicare.' Meanwhile, OBBBA is systematically removing Medicaid coverage for exactly this working-age population.
+
+This creates a structural contradiction: FDA is building digital health infrastructure for the Medicare population (which has better baseline access and outcomes) while coverage infrastructure deteriorates for Medicaid populations with demonstrably worse hypertension control. The KB already documents that only 23% of treated US hypertensives achieve blood pressure control, and that hypertension-related CVD mortality doubled 2000-2023. TEMPO's scale (10 manufacturers, research setting) cannot address population-level control failures, and its Medicare focus systematically excludes the populations most in need.
+
+The equity dimension is revealing: CMS ACCESS includes rural patient adjustments but no income-stratified or urban food desert measures. The ACP (Affordability Connectivity Program) subsidy for internet access was discontinued June 2024, removing the connectivity infrastructure TEMPO-eligible patients in low-income urban settings would need. This suggests TEMPO is optimizing for a Medicare research population with existing connectivity rather than expanding access to underserved populations.
+
+---
+
+Relevant Notes:
+- only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md
+- hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md
+- the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md
+- rpm-technology-stack-enables-facility-to-home-care-migration-through-ai-middleware-that-converts-continuous-data-into-clinical-utility.md
+
+Topics:
+- [[_map]]

domains/health/the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md

@@ -17,6 +17,12 @@ This two-track system has structural implications. It lowers the barrier for get
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm]] | Added: 2026-03-31*
+
+TEMPO pilot creates the next layer of FDA digital health deregulation beyond the January 2026 CDS guidance: enforcement discretion for uncleared devices deployed in real-world Medicare settings. This is a structured pathway for collecting the outcomes data that traditional FDA review requires, creating a workaround for the regulatory pathway problem where companies need data to get clearance but need clearance to collect data at scale.
+
+
 Relevant Notes:
 - [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]] -- the regulatory framework enabling the sensor stack to reach consumers
 - adaptive governance outperforms rigid alignment blueprints because superintelligence development has too many unknowns for fixed plans -- TEMPO's real-world evidence approach mirrors the adaptive governance principle

inbox/queue/2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm.md

@@ -7,9 +7,14 @@ date: 2025-12-05
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
 priority: high
 tags: [FDA, TEMPO, digital-health, enforcement-discretion, CMS-ACCESS, hypertension, cardio-kidney-metabolic, regulation, reimbursement]
+processed_by: vida
+processed_date: 2026-03-31
+claims_extracted: ["tempo-pilot-creates-medicare-digital-health-pathway-while-medicaid-coverage-contracts.md"]
+enrichments_applied: ["the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md", "CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo.md", "rpm-technology-stack-enables-facility-to-home-care-migration-through-ai-middleware-that-converts-continuous-data-into-clinical-utility.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -72,3 +77,15 @@ PRIMARY CONNECTION: `the FDA now separates wellness devices from medical devices
 WHY ARCHIVED: Represents a structural escalation of FDA's January 2026 digital health deregulation — from general CDS guidance to a specific real-world evidence collection pathway targeting hypertension. The Medicare/Medicaid structural contradiction with OBBBA is a high-value claim candidate.
 
 EXTRACTION HINT: Extract the TEMPO + OBBBA structural contradiction as a compound claim. Note the Medicare (TEMPO) vs. Medicaid (OBBBA) split — different populations, diverging infrastructure. The extractor should flag this for the broader "access infrastructure deteriorating while delivery infrastructure improves" pattern.
+
+
+## Key Facts
+- TEMPO pilot announced December 5, 2025 via Federal Register notice
+- Statements of interest opened January 2, 2026
+- Up to 10 manufacturers per clinical use area will be selected
+- Four clinical use areas: early CKM, CKM, musculoskeletal, behavioral health
+- Hypertension explicitly included in early CKM category
+- ACP (Affordability Connectivity Program) subsidy discontinued June 2024
+- National scale for hypertension: ~73 million affected US adults
+- CMS ACCESS model includes rural patient adjustment
+- Legal analysis sources: Wilson Sonsini, Manatt, ArentFox, McDermott